Gensight Biologics (France) Performance
| SIGHT Stock | EUR 0.33 0.04 10.81% |
The company retains a Market Volatility (i.e., Beta) of 0.16, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Gensight Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Gensight Biologics is expected to be smaller as well. At this point, Gensight Biologics has a negative expected return of -0.0192%. Please make sure to check out Gensight Biologics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Gensight Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Gensight Biologics SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Gensight Biologics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 37.9 M | |
| Total Cashflows From Investing Activities | -16 K |
Gensight |
Gensight Biologics Relative Risk vs. Return Landscape
If you would invest 36.00 in Gensight Biologics SA on September 4, 2024 and sell it today you would lose (3.00) from holding Gensight Biologics SA or give up 8.33% of portfolio value over 90 days. Gensight Biologics SA is generating negative expected returns and assumes 4.8569% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than Gensight, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Gensight Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gensight Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gensight Biologics SA, and traders can use it to determine the average amount a Gensight Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0039
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SIGHT |
Estimated Market Risk
| 4.86 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Gensight Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gensight Biologics by adding Gensight Biologics to a well-diversified portfolio.
Gensight Biologics Fundamentals Growth
Gensight Stock prices reflect investors' perceptions of the future prospects and financial health of Gensight Biologics, and Gensight Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gensight Stock performance.
| Return On Equity | -1.72 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (6.59) % | |||
| Current Valuation | 150.19 M | |||
| Shares Outstanding | 46.16 M | |||
| Price To Book | 50.99 X | |||
| Price To Sales | 33.81 X | |||
| Revenue | 5.28 M | |||
| EBITDA | (25.52 M) | |||
| Cash And Equivalents | 44.29 M | |||
| Cash Per Share | 1.06 X | |||
| Total Debt | 12.1 M | |||
| Debt To Equity | 14.40 % | |||
| Book Value Per Share | 0.07 X | |||
| Cash Flow From Operations | (17.14 M) | |||
| Earnings Per Share | (0.68) X | |||
| Total Asset | 56.65 M | |||
About Gensight Biologics Performance
Assessing Gensight Biologics' fundamental ratios provides investors with valuable insights into Gensight Biologics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Gensight Biologics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France.Things to note about Gensight Biologics performance evaluation
Checking the ongoing alerts about Gensight Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gensight Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gensight Biologics generated a negative expected return over the last 90 days | |
| Gensight Biologics has some characteristics of a very speculative penny stock | |
| Gensight Biologics has high historical volatility and very poor performance | |
| The company reported the revenue of 5.28 M. Net Loss for the year was (28.62 M) with profit before overhead, payroll, taxes, and interest of 7.71 M. | |
| Gensight Biologics SA has accumulated about 44.29 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Gensight Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gensight Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Gensight Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gensight Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gensight Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gensight Biologics' stock. These opinions can provide insight into Gensight Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.